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Abstract
Starting from late 2003 multiple outbreaks of highly pathogenic avian influenza type A H5N1 virus have occurred first in Southeast Asia 
and then in the rest of the world. There is a consensus that influenza pandemics will not fade away as illustrated by H1N1 swine flu 
outbreak this year. The possibility of a mutation which would cause more deadly virus spread in the human population is of particular 
concern. The human-to-human H5N1 transmission cases with fatal outcome have already been reported. There is unmet need for an 
effective vaccine to prevent bird flu outbreaks and potential human pandemic. Immunitor USA Inc is a start-up company which has 
developed the unique technology that enables the formulation of killed virus into an oral tablet. The vaccine consists of heat- and 
chemically-inactivated H5N1 virus which was expanded by a standard method in embryonated chicken eggs. The experimental lots of 
H5N1 oral vaccine have shown promising results in chicken challenge studies. However vaccine’s protection in terms of survival as the 
endpoint was partial and thus further studies are needed to identify optimally effective dose and vaccination schedule. These experiments 
will serve as proof-of-concept for developing an effective and safe vaccine capable of preventing and perhaps treating influenza virus 
infection. 
© 2010 Published by Elsevier Ltd. 
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1. Introduction 
During 2003-2004 seasons, the outbreaks of the avian influenza type A H5N1 virus have occurred in 57 of Vietnam’s 
64 provinces. This led Vietnam to cull over 40 million chickens and inflicted devastating losses on the local poultry 
farmers. In Thailand the disease has been detected in 40 of 76 provinces with 36 million birds culled as a result. In China 
16 out of 31 provinces, including Tibet, were hit by bird flu. The outbreaks of smaller magnitude occurred in South Korea, 
Japan, Indonesia, Myanmar, Cambodia, Laos, and Malaysia. By the end of 2004, avian flu has struck 11 Asian nations. 
The FAO estimated that close to 120 million chickens and other fowl have either died or culled in Asia during these 
outbreaks. In 2005 the outbreaks have spread further reaching Russia, Mongolia, Turkey, Greece, Romania, and Croatia. 
More recent reports have identified the presence of bird flu in migrating wild fowl in the Middle East, Africa, North 
America, and Western Europe. There is a consensus that avian flu outbreaks won't be eradicated by culling of domestic 
birds [1]. Even if seasonal outbreaks fade away there will be still the unmet need for a vaccine to prevent future incidents 
of pandemic flu virus such as current H1N1 swine flu virus.  
The threat of avian virus spread to human population is of particular concern. Over 380 human cases have been 
confirmed to date of which about two third have died [2]. Moreover, human-to-human H5N1 transmission with fatal 
outcome has been reported shortly after first outbreak [2,3]. Thus, the possibility of pandemic flu virus spread in global 
human population cannot be underestimated. According to the WHO figures, even regular seasonal influenza epidemic 
results in three to five million cases of severe illness and between 250,000 to 500,000 deaths each year in the industrialized 
world alone. Current H5N1 appears to be especially dangerous for humans as the mortality rate is 63% despite the fact that 
most infected patients were promptly treated with the best available influenza drugs such as Tamiflu or Relenza [2]. 
Immunitor USA Inc., is Maryland-based biotech company which has licensed oral vaccine technology to MDM Group 
Inc. Immunitor has developed unique technology that enables to formulate “killed” virus as an oral pill. Immunitor has 
manufactured experimental lots of H5N1 oral vaccine and evaluated their efficacy in a chicken model as a proof-of-
concept for developing human pandemic flu vaccine. The vaccine which is made as an oral tablet consists of heat- and 
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2. Materials and Methods 
2.1. Vaccine preparation 
The initial stock of virus was a wild-type isolate freshly isolated from a diseased farm chicken as kindly provided by 
Drs. Chaisingh and Suktinthai from the National Animal Health Institute, Kasetsart University, Thai Ministry of 
Agriculture [1]. As heterologous virus control we used H5N3 strain from the WHO reference stock. While this virus has 
shared H5 determinant it has unrelated neuraminidase subtype and was presumed to provide lesser protective effect. 
Viruses were grown in the allantoic cavities of 9-11-day old embryonated chicken eggs at 37oC for 24-48 hours. Allantoic 
fluid was harvested and used for vaccine preparation according to a proprietary process developed by us, which involves 
killing virus by heat and chemical means. Briefly, the procedure involves limited acid hydrolysis and heat treatment at 
120oC for several hours. The process is well established and has been validated for seven types of vaccines currently 
manufactured by Immunitor. The complete inactivation of virus has been confirmed by passages of obtained vaccine in 
chicken embryos.  
2.2. Challenge virus  
The challenge virus was the same H5N1 strain used for vaccine preparation. The infectious dose was established by 
titration in freshly isolated chicken lung fibroblasts. The prepared stock was kept frozen until used for challenge 
experiments. Chicken were challenged with the lethal dose equivalent to 6.8x106.5 TCID50 of H5N1 given intraorally in 0.1 
ml saline solution. 
2.3. Challenge experiments in chicken  
Adult layer chicken were given orally one vaccine tablet once per day for seven days and challenged the next day with 
lethal dose equivalent to 6.8x106.5 TCID50 of H5N1. Three to five chicken in each group were used for each challenge 
experiment. Controls included non-vaccinated group and H5N3 vaccinated chicken which were challenged with H5N1 
virus. The additional control consisted of sterile injectable preparation of H5N1 vaccine made from the same stock. 
2.4. Field experience 
A local farmer, who have heard that our vaccine may prevent bird flu, decided to give pills to all his chicken. He gave 
two pills in one dose to approximately 50 adult chicken and one pill each to nine small chicks that were hatched recently.  
3. Results 
3.1. Challenge studies 
The results from the challenge experiment reveal that all 3 unvaccinated chicken in the control group were dead within 
30 hours. However, three and four out of five vaccinated chicken with H5N3 and H5N1 vaccines respectively were alive at 
this cut-off time (Table 1 and Figure 1). Based on these results it appeared that the protection conferred by H5N1 vaccine 
was 80% up to 42 hours. However the death was only delayed, not prevented, as all birds have died after 48 hours. The 
chickens vaccinated with control vaccine made from heterologous H5N3 virus were dead earlier. The Chi-Square analysis 
of surviving versus dead chicken with standard cut-off P value at 0.05 is in support of these observations. This non-
parametric analysis of preliminary data, while limited, indicated that only H5N1 vaccine was capable of producing 
statistically significant result (p=0.028). Nevertheless, the protection was of short duration and clearly not optimal.  
Table 1. Results from H5N1 challenge test at 30 hours post-infection 
 
 
 
*Not available since P value is assessed by Ȥ2 against control
Alive 
Intervention Dead 
Sick Normal 
Total P 
Control   3 0 0 3 NA*
H5N3 vaccine    2 2 1 5 0.074 
H5N1 vaccine      1 2 2 5 0.028 
chemically-inactivated H5N1 2004 isolate from a farm chicken in Thailand and expanded in embryonated chicken eggs 
[1]. The results of preliminary studies are presented in this paper. 
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Fig. 1 Survival of non-vaccinated control (Ŷ); H5N3 (ź) and H5N1 (Ɣ) orally vaccinated chicken after challenge with H5N1. 
As an additional control, to support the efficacy of vaccine, we have tested injectable preparation which consisted of the 
same per unit of weight vaccine dose but dissolved in a sterile saline solution. Chicken were primed with one dose of 
vaccine by i.m. injection at day one, followed by second priming injection 2 weeks later and then challenged by a lethal 
oral dose equivalent to 6.8x106.5 TCID50 of H5N1 after one week of rest period. The results of this experiment are shown 
in Table 2 and Fig. 2. Although one chicken became sick and died at 3 days post-challenge, the remaining four chicken 
have survived and were still healthy and alive 20 days after the challenge, at which timepoint they were sacrificed. No 
control vaccination with injectable H5N3 vaccine was performed since we did not anticipate positive results with 
injectable vaccine. No immunological or virus shedding studies were performed on vaccinated chicken.  
Table 2. Results from vaccination with injectable H5N1 vaccine 
Alive 
Intervention Dead 
Sick Normal 
Total P 
Control 3 0 0 3 NA*
H5N1 0 1 4 5 0.005 
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Fig. 2 Survival of control (Ŷ) and H5N1 (Ɣ) parenterally vaccinated chicken after challenge with H5N1 
3.2. Field experience 
While this experience is serendipitous by nature it is intriguing in the context of above results. About one week after all 
farm chicken had been vaccinated there was as a flu outbreak at the surrounding farms that had decimated the entire 
chicken population in the neighborhood. As chicken were bred in a free-range style the disease has spread to the farmer’s 
birds. Within three days all adult chicken and 5 out of 9 chicks were dead (Table 3 and Figure 3). While no protection was 
observed in adult chicken the protective effect in young chicks appears to be highly significant (p<0.00001). Although 
these results are anecdotal, this experience suggests that a single oral dose of vaccine may be effective in a field situation 
and that the efficacy might be dose- and/or age-related.  
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Table 3. Survival of farm chicken fed with H5N1 pills prior to outbreak 
Farm chicken  
(vaccine dose) 
Dead Alive Total P 
Adults (2 pills)  50 0 50 NA*
Chicks (1 pill)   5 4 9 <0.00001 
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Fig. 3 Survival of orally vaccinated chicken (Ŷ) and young chicks (Ɣ) at the farm that experienced bird flu outbreak. 
4. Discussion 
We were able to produce the first lot of vaccine within one week from the moment virus was inoculated into 
embryonated eggs. The first lot of vaccine was then tested for protection against H5N1 challenge in chicken. The results 
indicate that H5N1 vaccine was capable of delaying death (p=0.028) even though after 48 hours all vaccinated chicken 
were dead. As a control we used vaccine from unrelated H5N3 virus. While this virus has shared H5 determinant it has 
unrelated neuraminidase subtype and was presumed to provide lesser protective effect. As expected vaccine made from 
unrelated strain was statistically less effective (p=0.074) in delaying death from H5N1 heterologous challenge [4]. This 
appears to be due to the fact that in addition to H5, a glycosylation site within N1 determinant contributes to the high 
virulence of H5N1 [5]. Unfortunately no further challenge experiments were carried out to further confirm the significance 
of these findings. Nevertheless, the positive data from injectable vaccine experiment which demonstrated 80% survival 
suggest that our vaccine has a prophylactic potential when oral formulation and/or vaccination schedule are optimized. 
The results from field experiment appear to support this conjecture. All adult chicken were dead but 44% of young 
chicks have survived. We do not know the reason for this discrepancy. One explanation lies in almost one log difference 
between received vaccine doses and size of recepients. Adult chicken who received a total of 2 pills weigh about 2-3 kg 
each, but chicks weighed only 60-100g at the time when they were given a single pill. Another conceivable explanation is 
that unlike adult birds the chicks may have smaller number of gastroliths or pebbles in their gizzards and it is thus possible 
that the pill has been not ground-up and annihilated by gastric juices. Thus, the pill may have reached the gut in intact form 
– the site where the vaccine’s antigens needs to be absorbed and the mucosal immune response to antigens occurs.  
While protection observed in chicks is incomplete, i.e., 44%, the difference in survival compared to adult chicken was 
highly significant (<0.00001). The observed rate of protection was hardly surprising - so far the complete protection has 
been seldom observed in experimental avian flu vaccine trials reported by others [6-8]. For example only 50% protection 
was observed by Swayne et al., [9] with their H5N1 vaccine. The cross-protective capacity of the same vaccine can vary 
widely from 54.5% to 100% depending on the choice of challenge virus [10]. Also the post-vaccination timing for 
challenge appears to be critical. In the field study at two Hong Kong farms H5N1 infection was most likely to cause death 
in recently vaccinated chickens up to 18 days post-vaccination, but no deaths were observed after that period [11]. Indeed 
100% protection was observed when chickens were challenged one month after vaccination [12]. Similar findings were 
reported by another group from Harbin, which indicated that hemagglutinin-inhibition antibody became detectable one 
week after vaccination and reached a peak at six weeks post-vaccination [13]. Finally, the age of vaccinated chicken 
appears to play an important role in protection as has been reported by Schultz-Cherry et al., [14]. Indeed, their study has 
shown that H5N1 vaccine appears to be 100% effective in 2-week old chicken but partially protective in ovo and in one-
64  Vichai Jirathitikal and Aldar S. Bourinbaiar / Procedia in Vaccinology 2 (2010) 60–65
day-old chicks. We are thus confident that the level of protection conferred by our vaccine can be improved when factors 
such as age, timing of challenge and vaccine doses are taken into consideration in future studies.  
It is clear that growing highly pathogenic virus can be a challenge for scaled-up vaccine production. Beside low yield of 
virus due to pathogenic effect on chicken embryos, there is an inherent biohazard issue associated with handling the virus. 
For these reasons the virus stock for candidate vaccine needs to be selected from low pathogenic strains or recombinant 
viruses obtained by reverse genetics or other means must be used.  
Today the eminent danger of H5N1 pandemic is faded away but this experience has helped us to successfully make 
tableted vaccine (HAP-V) shortly after H1N1 swine flu outbreak has been reported in Mexico. However, our company is 
small and has no competitive advantage or established reputation to penetrate the prophylactic flu vaccine market. We 
have thus been entertaining the idea whether flu vaccine can be employed as a therapeutic strategy for acute and rapidly 
evolving infection like influenza. This possibility is backed by reports in the Russian medical literature which indicate that 
influenza vaccine when delivered by mucosal route can speed up the recovery process from flu symptoms, i.e., act as a 
therapeutic modality after infection has already been established [15]. In view of Russian data our vaccine needs to be 
tested as a therapy  - a property highly relevant in a situation when unvaccinated individuals are exposed to pandemic virus 
and start to display symptoms of the disease. Even if half of people are saved by such an intervention it can be a significant 
achievement especially considering the fact that less than a half of H5N1-infected individuals appear to survive despite 
treatment with Tamiflu or Relenza. 
In event there is a pandemic with highly pathogenic flu virus, like H5N1, our vaccine may become extremely valuable 
since as an oral pill it will be easier to distribute to a large number of people within very short period of time. In fact, the 
article published by Agafonov et al., [16] is highly illustrative of this advantage. During accidental smallpox outbreak in 
Moscow a vaccination team, consisting of 2-3 persons, was capable of vaccinating within one hour 1,456 persons by oral 
method, 891 by spray method, and only 27 people by injection. Thus, oral delivery is much faster than conventional 
methods – a factor very critical in emergency situations. Furthermore, oral delivery does not require medical training and 
substantial distribution-related expenses as it would be necessary for parenteral delivery means. Most people will certainly 
prefer taking the pill rather than subjecting themselves to needle injection. However, making vaccine as a pill has been 
historically a very challenging task [17]. Our technology represents the long-awaited breakthrough and is supported by 
data from clinical trials of our therapeutic vaccines for HIV and viral hepatitis B and C infections [18,19]. Furthermore, 
our recent clinical trial of therapeutic vaccine designed to treat chronic inflammatory diseases, such as obesity and 
atherosclerosis, provides additional support to the advantage of oral delivery [unpublished]. 
In conclusion, our results suggest that oral formulation of killed flu virus holds a promise as potentially effective 
prophylactic and therapeutic vaccine. However, it is clear that several factors are at play as revealed by this study. Further 
experiments need to be carried out to test variables such as feeding schedule, dose, timing of challenge, antibody and cell-
mediated immune responses, in order to identify the optimal vaccine formulation.  
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